Nuveen Asset Management LLC has purchased shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO).
According to the most recent Form 13F filing that Nuveen Asset Management LLC made with the SEC, the company increased ...
Tag: SGMO, Analyst Rating
Sangamo Therapeutics, Inc. is expected to earn ($0.38) per share in the first quarter of 2023. (NASDAQ:SGMO)
The company name is Sangamo Therapeutics, INC (NASDAQ: SGMO). Jefferies Financial Group released a research note on Sangamo Therapeutics on ...
Bank of America has downgraded Sangamo Therapeutics (NASDAQ:SGMO) to “Neutral.”
According to a report on Briefing.com, analysts from Bank of America lowered their recommendation for Sangamo Therapeutics (NASDAQ: SGMO), moving ...